Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 24 Corporate Ct GUELPH ON N1G 5G5 |
Tel: | N/A |
Website: | https://www.zentek.com |
IR: | See website |
Key People | ||
Gregory Fenton Chief Executive Officer, Director | Wendy Ford Chief Financial Officer | Colin Van Der Kuur Vice President - Science and Research | Ryan Shacklock Vice President - Strategy, Business Development and Investor Relations |
Business Overview |
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company's developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis. |
Financial Overview |
For the six months ended 30 September 2024, Zentek Ltd revenues increased 82% to C$21K. Net loss decreased 15% to C$5.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 90% to C$97K (expense), Salaries and benefits decrease of 20% to C$1.6M (expense), Consulting fees decrease of 76% to C$75K (expense). |
Employees: | 25 as of Mar 31, 2024 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $161.10M as of Sep 30, 2024 |
Annual revenue (TTM): | $0.04M as of Sep 30, 2024 |
EBITDA (TTM): | -$9.78M as of Sep 30, 2024 |
Net annual income (TTM): | -$10.74M as of Sep 30, 2024 |
Free cash flow (TTM): | -$7.03M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 104,064,815 as of Sep 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |